DAX ®12.674,88+0,66%TecDAX ®3.057,16+1,97%S&P 5003.351,69+0,07%NASDAQ11.137,91-1,10%
finanztreff.de

PRESS RELEASE: curasan AG: curasan AG postpones annual financial report 2019 to 31 July 2020

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: curasan AG / Key word(s): Annual Results
curasan AG: curasan AG postpones annual financial report 2019 to 31 July
2020

2020-06-30 / 16:10
The issuer is solely responsible for the content of this announcement.

*curasan AG: curasan AG postpones annual financial report 2019 to 31 July
2020*

Kleinostheim, Germany, 30 June 2020 - The Management Board of curasan AG
(shares: ISIN DE000A2YPGM4 / convertible bond: ISIN DE000A2TR497) announces
that the publication of the annual financial report 2019, originally planned
for 30 June 2020, will be postponed to 31 July 2020. The reason for the
delay is that the binding offer submitted by Donau Invest Beteiligungsges.
m.b.H., Vienna, which is to be implemented in the insolvency plan, still has
to be examined by the auditor with regard to the continuation prognosis.

*Contact curasan AG:*
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

*About curasan AG:*
curasan develops, manufactures and markets biomaterials and medical devices
in the field of bone and tissue regeneration, wound healing and
osteoarthritis therapy. As a pioneer and global technology leader in the
growing field of regenerative medicine, curasan is specialized primarily on
biomimetic bone grafting materials for dental, oral/maxillofacial,
orthopedic and spinal applications, i.e. materials mimicking biological
structures. Numerous patents and a broad record of scientific publications
demonstrate the clinical success of the products and the highly innovative
strength of curasan. Dental and orthopaedic clinicians worldwide benefit
from the broad range of the premium quality and easy to use portfolio
offered by the technology leader curasan. curasan maintains its own
high-tech facilities for research, development and manufacturing of
biomaterials in Frankfurt/Main, Germany. In addition to its headquarters,
the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh,
N.C., USA. curasan's innovative products are cleared by the US Food and Drug
Administration (FDA) and many other international authorities and available
in almost 50 countries worldwide. curasan AG is a public company listed in
the General Standard at the Frankfurt Stock Exchange.

2020-06-30 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE000A2YPGM4
WKN: A2YPGM
Listed: Regulated Market in Frankfurt (General Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 1082855

End of News DGAP News Service

1082855 2020-06-30



(END) Dow Jones Newswires

June 30, 2020 10:10 ET ( 14:10 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 33 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen